Aberrant EZH2 activity has been implicated in multiple cancer types, including lymphomas, prostate cancer, breast cancer, and melanoma. The dysregulation of EZH2 leads to the suppression of tumor suppressor genes and the promotion of oncogenic pathways. Therefore, targeting EZH2 with specific inhibitors presents a promising therapeutic strategy to restore normal gene expression patterns and inhibit tumor growth.
